'Pharmaceutical deficiency' — what the term gets wrong, the kernel it gets right

The phrase, plainly

“Pharmaceutical deficiency” is a rhetorical inversion. The everyday meaning of “deficiency” — too little of something the body needs — is being mapped onto medication. The implication is that mainstream medicine treats people as if they were “deficient” in the absence of a drug, and that the resulting prescribing is unnecessary or harmful.

The term does not appear in RACGP, eTG, NHMRC, AMH, NPS MedicineWise, TGA, or ACSQHC documents. No body has a physiological requirement for a synthetic drug; nothing is medically deficient in the absence of a prescription.

That said, the underlying concern — that some adults are on more medication than the evidence supports — is a serious, well-developed area of Australian general practice. This page covers both: the framing that does not hold up, and the legitimate prescribing-quality conversation underneath it.

A. The legitimate concern: appropriate prescribing

Inappropriate prescribing in either direction — over-prescribing or under-prescribing — is a real problem that AU general practice actively addresses.

Over-prescribing in specific contexts. The cleanest examples:

• Polypharmacy in older adults (five or more medications). Associated with falls, cognitive impairment, drug interactions, and reduced quality of life. The home-medicines review (MBS item 900) is the AU-specific structured response.
• Benzodiazepines in older adults. Choosing Wisely Australia recommends against ongoing benzodiazepine prescribing in adults over 65 except in carefully considered circumstances, due to fall and cognitive risk.
• Proton pump inhibitors continued past their original indication. A common deprescribing opportunity, with a structured tapering protocol in Australian Prescriber.
• Opioids in chronic non-cancer pain. The RACGP and Veterans’ MATES programs run substantial prescriber-feedback efforts on opioid prescribing patterns.
• Antibiotics for viral upper respiratory tract infections. AU antimicrobial stewardship programs, including NPS MedicineWise, are explicit about this as a high-yield deprescribing target.
• Multivitamins in healthy adults with no documented deficiency. Multiple AU reviews conclude no benefit and a small harm signal at population level.

Under-prescribing of trial-supported therapies. The mirror-image problem:

• Statins in high cardiovascular risk. The Heart Foundation 2023 guideline highlights that statins are prescribed for fewer than half of adults whose calculated five-year cardiovascular risk warrants them.
• Antihypertensives in confirmed hypertension. AIHW data shows substantial under-treatment of blood pressure relative to AU guideline thresholds — roughly one-third of Australian adults with hypertension achieve target.
• Anticoagulation in atrial fibrillation. Despite clear evidence and AU-specific risk calculators, a meaningful proportion of patients eligible for direct oral anticoagulants remain on aspirin alone or no antithrombotic therapy.
• Opioid substitution therapy in opioid use disorder. Substantially under-prescribed by population estimate.
• Disease-modifying anti-rheumatic drugs (DMARDs) in early rheumatoid arthritis. Treatment delay correlates with worse long-term outcomes; AU pathways aim for prompt initiation.

Both directions of mismatch matter. Both are addressed by the same answer: patient-specific, evidence-graded prescribing decisions, reviewed at intervals.

B. The framing this term misses

When “pharmaceutical deficiency” is deployed rhetorically, three implications usually travel with it:

Implication 1: Medication is generally unnecessary; lifestyle alone would do. This is partially true and partially not. For some conditions (mild hypertension in young adults, prediabetes, mild depression, early metabolic syndrome), lifestyle intervention as first-line is genuinely supported — and is what the RACGP, Heart Foundation, and Therapeutic Guidelines recommend. For others (atrial fibrillation, type 1 diabetes, established cardiovascular disease, moderate-to-severe depression, opioid use disorder, severe asthma, schizophrenia, epilepsy), lifestyle alone is not adequate and the trial evidence for medication is overwhelming.

Implication 2: Industry incentive drives prescribing in ways that harm patients. Pharmaceutical industry marketing does affect prescribing patterns — that is empirically documented. The AU response is layered: industry advertising of prescription medication to consumers is prohibited (unlike in the US), the Code of Conduct for the Medical Profession restricts what practitioners can accept from industry, prescriber-feedback programs (NPS, Veterans’ MATES) provide independent data on prescribing patterns, and continuing medical education is increasingly required to be industry-independent. The system is imperfect but real.

Implication 3: The alternative is to avoid medication when possible. This is sometimes correct (deprescribing in older adults, lifestyle first in low-risk hypertension) and sometimes catastrophically wrong (anticoagulation in atrial fibrillation, insulin in type 1 diabetes, statins after a heart attack, antipsychotics in schizophrenia, antiretrovirals in HIV). The decision is patient-specific; the blanket position “avoid medication” produces predictable harm in patients for whom medication is the established life-saving intervention.

C. The AU general practice structural response

The Australian quality-use-of-medicines (QUM) framework is the practical answer to the underlying concern.

NPS MedicineWise — national education and prescriber-feedback program. Generates QUM reports, provides decision-support tools, runs consumer education.

Veterans’ MATES program — feedback to GPs on prescribing patterns in veterans, with educational interventions on specific safety topics.

Choosing Wisely Australia — AU specialty colleges publish 5–10 specific recommendations each on low-value or potentially harmful practices to deprescribe or avoid.

Therapeutic Goods Administration — runs the Database of Adverse Event Notifications, conducts post-market surveillance, issues safety alerts.

Home-medicines review (MBS item 900) — pharmacist-led review of all medications a patient is taking, in their home, with a structured report to the GP. Particularly useful for polypharmacy, transitions of care, or complexity.

75+ Health Assessment (MBS items 701/703/705/707) — comprehensive review including medication, falls risk, cognition, mobility. Annual.

GP Management Plan + Team Care Arrangement (items 721 + 723) — structured plan for chronic conditions, including medication review and allied health access.

(MBS / PBS items verified 2026-05-16 via WebSearch — workspace egress to mbsonline.gov.au + pbs.gov.au still blocked; spot-check confirms current.)

Deprescribing as a discipline. Scott et al. (JAMA Intern Med 2015) set out a structured process: reconcile the medication list, identify potentially inappropriate medications, evaluate risk/benefit for each, plan tapering with the patient, monitor for rebound or recurrence. Page AT et al. (Br J Clin Pharmacol 2016) demonstrated feasibility and outcomes in older adults. AU-specific guidance is in Australian Prescriber.

D. What this means for an individual reader

If you’ve been told “pharmaceutical deficiency” is why people are sick, the AU primary-tier read on that is: the framing is rhetorical, the underlying concern about prescribing quality is real, and the legitimate version of the conversation has a substantial AU general practice infrastructure built around it.

For an individual considering whether their own medication regimen is appropriate, the AU-aligned next steps:

• Long consultation with the GP for medication review — MBS items 36 or 44 allow time to go through each medication, indication, evidence of benefit, current and historical side effects, and patient preference.
• Home-medicines review (item 900) if polypharmacy is present and the GP agrees the structured pharmacy-led review is warranted.
• Honest conversation about goals. Different patients reasonably weight functional status, longevity, side-effect burden, and out-of-pocket cost differently. Shared decision-making is the structural answer to “is this medication right for me”.
• Caution about wholesale stopping. Stopping anticoagulants without supervision can precipitate stroke. Stopping antiepileptics can trigger seizures. Stopping antidepressants abruptly can produce discontinuation syndromes. Stopping insulin can cause diabetic ketoacidosis. Deprescribing is staged, supervised, and reviewed.

Caution about marketing on the other side. Branded supplement regimes promoted as a substitute for trial-supported medications carry the same evaluation question — what is the trial evidence for this specific product for this specific indication in this specific patient. The honest comparison runs in both directions.

What this article is and is not

This is general health information drawn from current Australian general practice guidelines, RACGP standards, Therapeutic Guidelines, NPS MedicineWise resources, and Choosing Wisely Australia recommendations. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about starting, stopping, or modifying any specific medication are made with your own GP and treating clinicians, who know your history and can monitor changes.

For consumer-friendly AU sources: HealthDirect — Medicines, NPS MedicineWise consumer resources, and AIHW — Medicines reporting.

---

Sources cited

1. RACGP
2. Therapeutic Guidelines (eTG)
3. Australian Medicines Handbook
4. NPS MedicineWise
5. Choosing Wisely Australia
6. Australian Commission on Safety and Quality in Health Care
7. Veterans’ MATES program
8. Australian Prescriber
9. Heart Foundation — CVD risk guideline
10. AIHW — Medicines
11. HealthDirect
12. Medical Board of Australia — Code of Conduct
13. TGA
14. Scott IA et al. — Reducing inappropriate polypharmacy (JAMA Intern Med 2015)
15. Page AT et al. — Deprescribing in older adults (Br J Clin Pharmacol 2016)